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Abstract
Background: Lead (Pb) poisoning among people using opium has been an increasing problem in Iran. The present
study highlights the clinical effects of lead toxicity associated with opium use in Iran, Kerman province.
Methods: Between January 2016 and June 2016, patients with signs and symptoms of Pb poisoning were questioned
to assess whether they had a history of opium dependency. In total, 249 patients were enrolled onto this cross-
sectional study, all were opium dependent. Para-clinical data including blood lead level (BLL), demographic
information, user preferences, and symptoms were obtained.
Results: The patients used either opium (83.9%), refined opium (6.4%) or a combination of both (9.7%) via ingestion
(71.9%), smoking (8.4%) or a combination of both (19.7%). The overall median BLL was 80.0 μg/dL [IQR: 51.7–119.0]. The
median BLL did not differ significantly between opium and refined opium users. Further, BLL was not significantly
affected by the type of substance, route of use, duration of use, or daily quantity consumed. Common symptoms
included abdominal pain (86.9%), constipation (75.8%), anorexia (71.5%) and nausea (54.7%). Linear regression analysis
showed log of BLL was significantly associated with abdominal pain, myalgia and anorexia.
Conclusions: The study unravelled an increase in opium-related Pb poisoning in the Kerman province. Raised
awareness of this emerging Pb source and investigation of its aetiology is recommended. Pb poisoning should be
considered among the primary differential diagnosis of opium users with gastrointestinal symptoms.
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Background
Historically, lead (Pb) has been one of the most widely
used metals due to its useful properties such as low
melting point, high density and ductility. Decades of
widespread industrial and commercial use of leaded
products, most notably petrol and paint, have left a leg-
acy of environmental contamination which may contrib-
ute to chronic Pb exposure and acute Pb toxicity [1–4].
Chronic Pb poisoning appears progressively and is not
specific [5]. Chronic exposure may trigger an acute
presentation. The specific indications of acute lead tox-
icity involve abdominal pain (Pb colic), constipation,
irascibility, neuropathy, muscle inflammation, joint pain,
headache, anorexia, reduced sexual desire, concentration
and short-term memory problems, nausea, lead lines on
gums, anaemia, basophilic stippling of red blood cells,
and kidney diseases [6–8]. Many outcomes of lead tox-
icity are related to its interactions with crucial compo-
nents like calcium, enzymes and other proteins [9]. Lead
poisoning can result from ingesting or inhaling lead
compounds [10]. It can also occur as a result of dermal
contact with organic lead, though to a lesser extent, or
bone reabsorption of leaded bullets. Around 90–95% of
absorbed lead is reserved in the cortical bone and teeth,
liver, brain and kidneys. 75% of excreted lead is removed
by the kidneys; the remainder is eliminated via the
gastrointestinal tract, sweat, and skin or is accumulated
in the nails and hair [7, 11, 12].
In adults, the greatest absorption of Pb occurs via the
respiratory tract, where up to 95% can be absorbed in
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the lungs. When Pb is ingested approximately 5–20% is
absorbed, largely in the duodenum.
Diagnosis of Pb poisoning is based on elevated Pb
levels in the blood, specifically a BLL of ≥10 μg/dL. Dis-
continuation of contact with the lead source is a vital
step in treatment. Most outcomes of lead poisoning can
be reversed if lead toxicity is diagnosed swiftly and the
source eliminated. Chelation therapy may be necessary
in acute Pb poisoning in order to more rapidly reduce
the BLL and facilitate recovery [6, 13].
Pb poisoning outbreaks around the world have typ-
ically occurred as a result of significant environmental
contamination from activities such as Pb mining or
smelting. Examples include the Pb poisoning outbreak
in Zamfara State, northern Nigeria, in which several
villages were affected by significant environmental Pb
pollution due to mining activities. Examples of un-
usual Pb incidents are also available in the literature
and include acute Pb poisoning occurring from the
use of topical Ayurvedic treatment [14, 15] and culin-
ary spices [16, 17].
There are several accounts of Pb toxicity arising from
drug use, most involving opium [11, 20], though reports
of cases involving marijuana [18] or methamphetamine
[19] are also available. The earliest account of lead con-
taminated opium was in 1973 and was as a result of
cross contamination from the kitchen equipment used
to prepare opium for consumption [20].
The process of mass opium manufacture typically in-
volves reducing opium poppies to brown sticky paste
and sun drying, during which impurities such as Pb may
be introduced or concentrated [21–23]. Refined opium,
locally referred to as Shireh, is a strong opium produced
by refining raw opium, known locally as Taryak, in boil-
ing water, heating and filtering to remove insoluble ma-
terials [24].
Several sources of Pb contamination have been postu-
lated in the literature: the adulteration of opium with Pb
to increase weight, either at the point of production or
at a local level [7, 25]; contamination from the process-
ing equipment used during the production of the opium
[20, 26]; and/or contamination of land on which opium
is grown [27, 37]. It is suggested that other compounds
like lead oxide, lead nitrate, lead acetate as well as Indian
hair colours which contain lead can also be added to
opium [27].
Some Iranian researches have analytically confirmed
the presence of Pb in opium [6, 25]. Several others have
reported lead toxicity in opium users [5, 26, 28, 29].
Iran shares a border with Afghanistan, a major produ-
cer of opium, and exportation of opium across this
border has been identified as one of the main routes for
transit of opium worldwide [30, 31]. Consequently,
opium availability and use is a major issue in Iran, which
may create a platform for opium adulteration and an in-
creased risk of acute Pb exposure [30, 31].
It has been shown that Pb readily accumulates in the
capsule of poppy plants grown in Pb contaminated soil
[32]. Afghanistan, provides about 90% of the world’s opium
[33]; the United Nations Office on Drugs and Crime
reports that that average yield of opium has increased in
certain parts of central and southern Afghanistan [34].
Afghanistan’s Pb mineral rich deposits and Pb mines are
also largely distributed in these regions [35] so it follows
that an increase in opium production grown on Pb
contaminated land could potentially increase the Pb
concentration in opium, this warrants further investigation.
It is feasible that multiple sources are responsible for
the lead content in opium, herein lies a gap in the
current knowledge. What is clear from published case
reports and this current study, is that the number of
opium users being admitted to hospitals for Pb poison-
ing appears to be increasing in Kerman and other parts
of Iran [29, 36].
Meybodi determined that the prevalence of opium user
patients with Pb poisoning in Tehran, Iran’s capital city,
over a one-year period (2006 and December 2007) was
limited to 25 patients [28]. In 2009 a study in Kerman
showed no significant difference in the BLL of opium
users (n = 50) and the control group (n = 43) [37].
Although in recent years there has been an increase in
cases of lead poisoning due to opium use in some cities
of Iran such as Birjand and Ardabil [8, 23], Pb poisoning
related to opium use had until recently remained rela-
tively rare and to our knowledge such poisoning was
generally only reported as isolated cases.
The study herein highlights an acute increase in cases
of lead poisoning of opium users reported over a short
time period in Kerman Province, Iran. The aetiology of
this increase is unknown. Given the severe outcomes of
significantly increased serum level of Pb, this study also
examines the clinical effects of acute Pb poisoning in
opium users.
Method
Between January 2016 and June 2016, all patients with
signs and symptoms of Pb poisoning were questioned to
ascertain whether they had a history of opium depend-
ency. Opium dependency was evaluated according the
Diagnostic and Statistical Manual of Mental Disorders -
Fourth Edition (DMS-IV) criteria. All patients admitted
to the hospital with suspected Pb poisoning were
assigned to opium-dependant group (hereafter referred
to as opium users) according to the DMS-IV criteria.
The assessment was conducted by a clinical toxicolo-
gist or gastroenterologist at Afzalipour hospital, the
main toxicology and gastroenterology centre in Kerman
province [38].
Hayatbakhsh et al. Substance Abuse Treatment, Prevention, and Policy  (2017) 12:43 Page 2 of 8
Two hundred forty-nine patients were enrolled onto
this cross-sectional study using the census method. The
inclusion criteria involved initial diagnosis of Pb toxicity,
being over 18 years old, opium-dependency according to
the DMS-IV criteria and having the desire to participate
in the study. The exclusion criteria included those with
pre-existing diseases (such as anaemia or liver, kidney
and gastrointestinal conditions), those with a history of
environmental or occupational exposure to lead as well
as other drug use. According to the DSM-IV, an individual
was classified opium-dependent when three of the
following symptoms were experienced within the last
12 months: (1) tolerance to opium, (2) opium withdrawal
when not consuming opium, (3) the need to increase the
dose of consumed opium over time, (4) constant desire to
quit or reduce opium use, (5) spending a great deal of time
preparing to use, or recovering from the effects of use, (6)
reducing time spent in social, occupational, or recreational
environments, and (7) continuing opium consumption
despite experiencing physical or psychological problems
associated with its use.
Blood samples (5 ml) were collected from the cubital
vein into heparinized tubes and stored at -20 °C. Blood
Pb content was analysed by atomic absorption spec-
trometry (Varian Co., US) according to NIOSH
standard method. A qualified doctor examined the
patients and completed the questionnaire. Details of
demographic data (age, gender and employment status),
signs and symptoms, user preferences such as daily
quantity consumed, route of administration and para-
clinical data were collected according to a standardized
checklist.
Biochemical concentrations of BLL, haematocrit,
haemoglobin, blood urea, creatinine, alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
were recorded for subsequent analysis.
Ethical approval was granted by the Ethics Committee
of Kerman University of Medical Sciences. Written
and informed consent was taken from the patients
after they were consulted on the study objectives,
responsibilities of participants and researchers in the
study, data collecting and recording techniques, confi-
dentially and the use of data for publishing in scien-
tific journals. No patient identifiable information is
disclosed in this paper.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 22.0, IBM Co., Chicago, IL). P-values <0.05 were
considered as statistically significant. To explore the
data, descriptive statistics (mean, standard deviation
(SD), frequency, and percentage) were evaluated. The
Shapiro-Wilk test was used to test normal distribution
of numerical variables. The Student T-test or Mann-
Whitney was used for two-group comparisons of con-
tinuous variables. Where the data followed a normal dis-
tribution, comparison was achieved by one-way
ANOVA. Kruskal-Wallis test was used where data were
skewed. In order to assess the relationship between BLL
and haemoglobin, haematocrit, the Pearson correlation
test was used. Associations between BLL and clinical
symptoms, type of substance, route of use, duration of
use or daily quantity consumed were evaluated by linear
regression analysis; a level lower than 5% was considered
significant.
Results
In total, 249 patients were included in the study, 79% of
which were male. The average age of cases was
48.5 ± 14.1 years (20–91 years). The mean BLL was
91.02 ± 59.83 μg/dL. The data were right-skewed, with a
median BLL of 80.0 μg/dL [IQR: 51.71–119.00]. BLL
ranged from 26 μg/dL to 350 μg/dL. According to
Mann–Whitney U test, there was no difference in the
median BLL of male (80.5 μg/dL [IQR: 51.73–120.0] and
female (78.0 μg/dL [IQR: 43.0–113.75] patients
(z = 0.83, p = 0.41).
The majority of patients (83.9% (n = 209) used solely
raw opium, 6.4% (n = 16) used solely refined opium and
9.7% (n = 24) used a combination of both raw and re-
fined opium. The median BLL of sole raw opium, refined
opium and opium plus refined opium users was
80.50 μg/dL [IQR: 51.54–117.0], 110.0 μg/dL [IQR:
58.0–159] and 70.88[IQR: 39.0–91.0] respectively. Ac-
cording to Kruskal-Wallis test, there was no significant
difference between BLL and type of substance (χ2 = 2.95,
p = 0.23) (Table 1).
One hundred seventy-nine patients (71.9%) were oral
users, 21 (8.4%) smoked and 49 (19.7%) used a combin-
ation of smoking and ingesting. There was no significant
difference in BLL associated with mode of use (Table 2).
One-way ANOVA showed that there was no significant
difference between duration of use (F (2246) = 0.19,
p = 0.83), daily quantity consumed (F (2246) = 2.28,
p = 0.11) and user drug preference (raw opium alone; re-
fined opium alone; and combination of both) (Table 3).
Similarly, there was no significant difference between
duration of use (F (2246) = 0.1, p = 0.90), daily quantity
consumed (F (2246) = 0.53, p = 0.59) and route of admin-
istration (smoking, oral, combination of both) according
to one-way ANOVA (Table 4).
Table 1 shows the median BLL, haematocrit, haemo-
globin, blood urea, creatinine, AST and ALT concentra-
tions of the patients. Spearman’s r indicated an
association between haemoglobin and BLL (r = −0.14,
p = 0.04) among all user groups (Fig. 1). There was no
significant relationship between BLL and haematocrit
(r = 0.13, p = 0.06). Blood urea and creatinine levels
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were unremarkable among all groups. Compared to ref-
erence levels, 25% of the patients had elevated levels of
ALT in the groups that used raw opium or raw opium
plus refined opium. ALT was not elevated amongst the
patients using solely refined opium. 42.4% of the patients
had increased levels of AST in the groups that used raw
opium or raw opium plus refined opium. There were no
cases with elevated AST in the group using solely re-
fined opium. There was a marked difference in AST in
the male and female patients with 37% of the male pa-
tients exhibiting elevated AST compared to just 7.4% for
female patients.
The six-month prevalence of signs and symptoms were
as follows:
Gastrointestinal complains including abdominal pain
(86.9%), constipation (75.8%), anorexia (71.5%) and nau-
sea (54.7%) were the most common signs and symptoms.
Other signs and symptoms included weakness (47.4%),
arthralgia (38.1%), myalgia (33.2%), insomnia (32.8%)
and peripheral neuropathy (3.7%).
BLL concentrations were right-skewed and were natural
log-transformed for linear regression analysis. Geometric
mean and ratio of geometric mean estimates were back-
transformed. Our data indicated the linear regression
model was statistically significant (F = 1.98, p = 0.04). Lin-
ear regression analyses for log of BLL were not signifi-
cantly associated with type of substance (B = 0.36,
t = 1.67, p = 0.09); route of use (B = 0.23, t = 1.44,
Table 1 Biochemical analysis of all users of raw opium, refined opium and combination users





Opium + refined opium
n = 24
F/X2 p-value
BLLa (μg/dL) 80.5 [51.5–117.0] 110.0 [58.0–159.0] 70.9 [39.0–91.0] 2.95 0.23
Haematocrit b (%) 33.5 ± 6.9 33.7 ± 3.7 34.4 ± 7.2 0.15 0.85
Haemoglobin b (g/dL) 10.5 ± 2.3 11.2 ± 2.1 10.6 ± 2.6 0.83 0.43
Blood Ureab (mg/dL) 28.8 ± 13.2 26.1 ± 12.7 33.6 ± 21.7 1.19 0.72
Creatinineb (mg/dL) 1.1 ± 0.9 0.9 ± 0.2 1.0 ± 0.1 0.10 0.91
ASTa (U/L) 46.0 [29.0–68.0] 27.0 [26.0–46.0] 41.5 [31.2–72.7] 2.86 0.23
ALT a(U/L) 36.0 [20.0–60.0] 21.0 [14.0–33.0] 30.0 [19.0–45.0] 2.87 0.24
Blood lead level (BLL) median concentration [IQR]; hematocrit; hemoglobin; blood urea; creatinine; aspartate transaminase (AST) and alanine transaminase (ALT)
mean concentrations (+SD) amongst the different user groups (raw opium; refined opium; and combination users)
Degrees of freedom for hematocrit, hemoglobin, blood urea, creatinine (dfb = 2, dfw = 246)
Degrees of freedom for BLL, AST, ALT (df = 2)
a compared using Kruskal Wallis test
b compared using one way ANOVA
Table 2 Median BLL across the users groups
Type of substance Route of use Blood lead level a (μg/dL)
Median [IQR] Minimum Maximum X2 p-value
Opium (taryak) Smoking (n = 12) 80.0 [45.7–110.0] 36.0 126.0 0.17 0.92
Oral route (n = 154) 80.0 [51.7–120.0] 26 350
Smoking + oral route (n = 43) 85.0 [51.0–116.0] 30 235
Refined opium (shireh) Smoking (n = 5) 96.5 [19.7–143.2] 70 150 2.37 0.31
Oral route (n = 10) 140.0 [66.5–170.5] 58 250
Smoking + oral route (n = 1) 55.7 [55.7–55.7] 55.7 55.7
Opium (Taryak) + refined opium Smoking (n = 4) 48.3 [39.0–56.4] 39 58 2.51 0.28
Oral route (n = 16) 72.1 [38.2–88.7] 27 200
Smoking + oral route (n = 4) 90.0 [54.8–156.5] 52 205
Total Smoking (n = 21) 70 [39.8–110.0] 36 150
Oral route (n = 180) 80.0 [51.2–120.7] 26 350
Smoking + oral route (n = 48) 85.0 [52.4–113.0] 30 235
Median blood lead level (BLL) differences between routes of administration (smoking, oral and combination users) across the user groups (raw opium; refined
opium; and combination users)
a compared using Kruskal Wallis test
Degrees of freedom for BLL (df = 2)
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p = 0.15); duration of use (B = 0.009, t = 0.63, p = 0.53)
and daily quantity consumed (B = 0.08, t = 0.29, p = 0.77).
Additionally, linear regression analysis showed log of BLL
was significantly associated with abdominal pain
(B = 0.98, t = 1.89, p = 0.03), myalgia (B = 1.16, t = 2.12,
p = 0.006) and anorexia (B = 0.58, t = 1.79, p = 0.04)
(Table 5).
Discussion
Pb poisoning in opioid users may currently be one of
the most important forms of non-occupational Pb poi-
soning in Iran. Opium use is widespread in Iran and the
clinical consequences of large plasma concentrations of
Pb can severe and debilitating.
Although, in general, drug services for users of opium
are extensive in Iran, a robust public health response to
the growing problem of Pb contaminated opium appears
to be lacking; the relatively small numbers previously af-
fected may not have warranted great resources.
The overall median BLL 80.0 μg/dL [IQR: 51.7–119.0]
(mean BLL 91.02 ± 59.83 μg/dL) of opium users in the
current study was markedly elevated compared to other
studies [6, 25, 39–41] which implies that the
concentration of lead in opium may be increasing. For
example, Khatibi-Moghadam et al., Ghaemi et al. and
Salehi et al. reported a mean BLL in opium users of
7.14 ± 1.41 μg/dL (n = 40), 8.03 ± 6.03 μg/dL (n = 33) and
21.9 ± 13.2 μg/dL (n = 22) respectively [7, 23, 42]. Gastro-
intestinal symptoms, including abdominal pain, had the
highest prevalence rate over the study period. Abdominal
discomfort in these patients can be mistaken for many
other diseases, and as a consequence may lead to unneces-
sary gastrointestinal imaging, laboratory tests, time wast-
ing and increased risk of deteriorating condition [43]. For
instance, Meybodi et al. and Mokhtarifar et al. presented
examples of patients with abdominal pain caused by Pb
Table 3 Duration of use and daily quantity of consumption
against the type of substance






Opium (n = 209) 15.25 ± 9.96 0.87 ± 0.54
Refined opium (n = 16) 16.84 ± 10.56 0.87 ± 0.75
Opium + refined opium (n = 24) 14.81 ± 8.27 1.22 ± 1.13
Test results F = 0.19, p = 0.83 F = 2.28, p = 0.11
Mean (+SD) years of consumption and the quantity consumed in grams
per day (g/day) across the user groups raw opium, refined opium and
combination users
Degrees of freedom for time consuming and quantity consumed
(dfb = 2, dfw = 246)
a compared using one way ANOVA test
Table 4 Years of opium consumption and quantity consumed
per day against the different routes of administration






Smoking (n = 21) 14.07 ± 9.18 1.16 ± 1.06
Oral route (n = 179) 15.13 ± 10.04 0.90 ± 0.57
Smoking + oral route (n = 49) 15.38 ± 8.83 0.93 ± 0.79
Test results F = 0.1, p = 0.90 F = 0.53, p = 0.59
The mean (+SD) years of consumption and the quantity consumed in grams
per day (g/day) across for the different routes of administration (smoking; oral;
and combination users)
Degrees of freedom for time consuming and quantity consumed
(dfb = 2, dfw = 246)
a compared using one way ANOVA test
Fig. 1 Relation between Blood Lead Level and hemoglobin
Table 5 Univariate linear regression analysis for associations
between BLL and clinical symptoms, type of substance, route of
use, duration of use or daily quantity of consumption
Variable B (SE) 95% CI t p-value
Type of substance (opium) 0.36 (0.22) −0.1, 0.79 1.67 0.09
Route of use (oral route) 0.23 (0.16) −0.1, 0.55 1.44 0.15
Duration of use 0.009 (0.01) −0.02, 0.04 0.63 0.53
Daily quantity of consumption 0.08 (0.26) −0.44, 0.60 0.29 0.77
Abdominal pain (yes) 0.98 (0.25) 0.85, 1.05 1.89 0.03
Constipation (yes) 0.13 (0.31) −0.09, 0.68 0.75 0.68
Arthralgia (yes) 0.05 (0.33) −0.05, 0.24 0.23 0.88
Myalgia (yes) 1.16 (0.34) 1.08, 1.38 2.12 0.006
Anorexia (yes) 0.58 (0.30) 0.34,0.72 1.79 0.04
Nausea (yes) 0.32 (0.33) −0.08, 0.65 0.99 0.33
Peripheral neuropathy (yes) 0.71 (0.69) −0.1, 0.98 1.12 0.30
Weakness (yes) 0.19 (0.33) −0.05, 0.85 0.61 0.55
Insomnia (yes) 0.21 (0.28) −0.04, 0.83 0.77 0.44
F = 1.98, dfb = 13, dfw = 236, p-value = 0.04
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poisoning which were mistakenly diagnosed as kidney
stones, cholecystitis, acute abdomen or generalized ileus
[28, 44]. As a result, it was suggested that an analysis of
blood Pb should be included while evaluating patients
who use opium and have unexplained abdominal pain [6].
The present study indicated a weak relationship be-
tween BLL and haemoglobin, Domeneh et al. and Beghé
et al. also reported a similar weak relationship, however,
in these two studies, age was reported as a predictor of
anaemia. Poor nutrition and lack of adequate self-care
can also accompany advanced drug use and may
contribute to anaemia particularly in older drug users
[29, 45]. In our study, the majority of participants were
in their middle age.
Biomarkers for liver injury were compared across
groups and to reference levels. There were elevated
plasma levels of ALT and AST in 36% and 42.4% of cases
respectively, though interestingly, not in those using the
refined opium (Table 1). The reason for this is unclear
as no other associations, including BLL and liver disease,
could be established. Is it feasible that other metals and
contaminants were present in greater concentrations in
the raw opium but due to scope and design of the study
these factors were not investigated. It would be valuable
to include analysis of other known opium contaminants
in future study designs. There were also stark differences
in levels of AST in males and females; females had far
less incidence of elevated AST. This also appears to be
unrelated to BLL as there were no differences in BLL be-
tween the males and females. There were no appreciable
differences in renal biomarkers.
Most individuals in this study were oral consumers of
opium, similar results have been reported in other stud-
ies [46, 47]. It was expected that smokers of opium
would have increased BLLs in comparison to those that
orally consumed, however, there was no significant dif-
ference among these groups. Complete volatilization of
Pb is dependent on the temperature exerted upon it; it is
possible that the temperature generated in the smoking
of opium does not fully liberate Pb vapour or a portion
of the vapours escape without being inhaled resulting in
decreased absorption via inhalation. Absorption follow-
ing ingestion of opium may be affected by nutritional
status, pH and transit through the digestive tract. Opi-
oids decrease gastrointestinal motility; thus, constipation
may result in greater absorption of Pb into the blood-
stream through prolonged intestinal exposure. Future
studies could include a comparison of the level of con-
stipation against BLL. It would also be of interest to
trace a possible “cocktail effect”, i.e. to explore the
possible combined toxic actions of other narcotics and
Pb and/or other heavy metals, that may lead to lower
critical levels for Pb exposure in drug users compared to
healthy population.
The frequency of raw opium users (n = 209) was sig-
nificantly greater than refined opium users (n = 16),
which may simply be due to differences in the popularity
of raw opium over refined opium, potentially due to cost
or drug effect. It could be speculated that a reduction in
opium Pb content due to the refinement process de-
creases the incidence of Pb poisoning in users of refined
opium. However, in our groups, the BLL was not signifi-
cantly different between refined opium and raw opium
users. Further, the refinement process, which involves
boiling raw opium pulp, is unlikely to significantly re-
move heavy metals.
The difference in group sizes places limitations on the
interpretation of our findings. It would be of interest to
conduct a study with comparable group sizes, ideally in-
corporating controls consisting of participants who use
opium without Pb poisoning and participants not using
opium but with Pb poisoning. Another limitation of this
study was that no analysis of opium Pb content was con-
ducted because of difficulties in obtaining opium sam-
ples from the patients; this should be considered for
future studies. Although not confirmed by opium ana-
lysis, patients’ drug use, diet, patient history, lifestyle, oc-
cupation, and the presence of pica (the consumption of
non-nutritive substances) were examined and no associ-
ations were found. During the study, there were no cases
of lead poisoning admitted to the hospital in populations
not using opium; it is therefore reasonable to assume
that the source of lead poisoning in the study group was
the opium.
Conclusion
Based on the findings of our study it is apparent that
there has been an increase in the frequency of acute Pb
poisoning amongst opium users in the Kerman province.
The reason for this spike in numbers remains unclear
and warrants investigation. Raised awareness of this Pb
source is recommended. Pb poisoning should be consid-
ered among the primary differential diagnoses of opium
users with gastrointestinal symptoms to assist in early
diagnosis and prevent further complications.
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